Recipient of the Dr. Sudipta Mohanty Scholarship for Healthcare Equity Announced
Boston, MA - The Dr. Sudipta Mohanty Scholarship for Healthcare Equity is thrilled to unveil its very first awardee. This unique $1,000 scholarship, initiated by Dr. Sudipta Mohanty, aims to uplift undergraduate students and aspiring physicians who are driven to enhance healthcare availability for underserved populations.
Dr. Sudipta Mohanty, a devoted physician and champion of fair healthcare, launched this program to nurture the ambitions of students eager to tackle disparities in medical access. The impressive volume of applications received from across the country underscores the rising dedication among young healthcare enthusiasts to transform primary care and uplift community wellness.
Supporting Tomorrow's Healthcare Pioneers
The Dr. Sudipta Mohanty Scholarship for Healthcare Equity is designed to bolster students who are passionate about primary care and serving overlooked communities. Candidates were tasked with submitting an essay exploring medicine's role in underserved regions and offering creative ideas to boost healthcare reach.
On March 15, 2025, one exceptional student was named the scholarship's inaugural recipient. This individual's essay will be showcased, celebrating their commitment to healthcare justice and their promise as a future leader in the field.
Dr. Sudipta Mohanty shared his excitement about the scholarship's mission: 'As a physician, I've witnessed the struggles underserved groups face in securing proper medical care. This scholarship is my effort to inspire and equip the next wave of healthcare providers to close these divides. The future of medicine hinges on compassionate, equity-focused individuals.'
Dr. Sudipta Mohanty's Legacy of Care
Dr. Sudipta Mohanty has built a career rooted in primary care, health advocacy, and teaching. His remarkable journey saw him begin college at age 15, later earning a medical degree from the University of Pittsburgh and completing residency training at the University of California Riverside. This path sharpened his focus on patient-first care and health system improvements.
A tireless proponent of expanding healthcare access, Dr. Mohanty's scholarship embodies his lifelong mission by aiding students who share his vision for change in underserved regions.
Countdown to March 15, 2025
The review process for the Dr. Sudipta Mohanty Scholarship for Healthcare Equity completed with a panel carefully evaluating submissions to select a winner who reflects the initiative's core values. The chosen student was announced on March 15, 2025, with their inspiring story spotlighted to motivate others in the medical community.
This scholarship not only provides financial aid but also fosters dialogue about making healthcare more inclusive. Dr. Sudipta Mohanty is eager to sustain this effort, championing the development of future healthcare trailblazers.
For additional details about the Dr. Sudipta Mohanty Scholarship for Healthcare Equity and upcoming opportunities, visit https://drsudiptamohantyscholarship.com/
Media Contact
Company Name: Dr. Sudipta Mohanty Scholarship
Contact Person: Dr. Sudipta Mohanty
Email: Send Email
City: Boston
State: Massachusetts
Country: United States
Website: https://drsudiptamohantyscholarship.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
16-05-2025
- Cision Canada
Brain Canada Invests in Six Montreal-Area Platforms to Drive Open Science Innovation Français
MONTRÉAL, May 16, 2025 /CNW/ - Six exceptional research platforms located in Montreal have been awarded funding through Brain Canada's Platform Support Grants program. With this support, these platforms will foster partnerships across research disciplines and power solutions for people living with brain conditions. From biobanks to databases and standardized protocols, these unique platforms highlight the significant role infrastructure plays in Canada's research ecosystem. The Canadian Open Neuroscience Platform Dr. Alan Evans, The Neuro (Montreal Neurological Institute-Hospital), McGill University The Douglas-Bell Canada Brain Bank: Supporting human brain research in Canada and beyond Dr. Gustavo Turecki and Dr. Naguib Mechawar, Douglas Institute, McGill University Advancing Brain Research Through Spatial Histology Dr. Marie-Christine Guiot, Goodman Cancer Institute and The Neuro (Montreal Neurological Institute-Hospital), McGill University The SLEEP HUB: An open science ecosystem for transforming sleep research Dr. Nadia Gosselin, CIUSSS du Nord de l'Île-de-Montréal and Université de Montréal EthoLab: A platform for neurophysiological studies of natural behavior Dr. Paul Cisek, Centre for Biomedical Innovation, Université de Montréal The NECTAr platform: A pan-Canadian platform dedicated to Neonatal hypoxic-ischemic Encephalopathy — For patient Care optimization, Training, and education Dr. Pia Wintermark, The Montreal Children's Hospital and The Research Institute of the McGill University Health Centre (Child Health and Human Development Program) Brain Canada's flagship Platform Support Grants (PSG) program aims to support interdisciplinary collaboration and enhance Canada's technical and research capabilities through shared tools and databases, to transform research into real world impact. "Unlocking the brain's complexities depends on reliable infrastructure and open access to scientific tools," said Dr. Viviane Poupon, President and CEO of Brain Canada. "This investment will strengthen a culture of Open Science so that specialized knowledge can benefit everyone." Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. These Montreal based platforms serve as hubs for researchers to work together towards the common mission of advancing our understanding of neuroscience and mental health. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. Brain Canada is proud to highlight these six platforms that are driving progress not only in Montreal but across Canada, and around the world. ABOUT THE PROJECTS The Canadian Open Neuroscience Platform (CONP) Dr. Alan Evans, The Neuro (Montreal Neurological Institute-Hospital), McGill University Total grant amount: $2,850,000.00 Many of the challenges faced by both basic and clinical neuroscientists can be tackled with open science approaches. To achieve these goals, Dr. Evans and his team have built the Canadian Open Neuroscience Platform (CONP), which aims to make neuroscience research, data, and tools accessible to everyone, with the ultimate objective of accelerating scientific discovery and its eventual translation to disease treatments. Through CONP's online portal that provides open access to datasets and analysis tools, its "Evidence" open publication platform, and its development of data governance frameworks and toolkits to facilitate open data sharing, the platform takes a truly multifaceted approach to enabling Open Science practices in the field of neuroscience. The Douglas-Bell Canada Brain Bank: Supporting human brain research in Canada and beyond Dr. Gustavo Turecki and Dr. Naguib Mechawar, Douglas Institute, McGill University Total grant amount: $2,850,000.00 The Douglas-Bell Canada Brain Bank (DBCBB; one of the most important brain banks in the world, currently houses and manages over 3,600 brains, as well as a large relational database containing demographic, clinical and developmental histories from brain donors with different neurodegenerative diseases (e.g., Alzheimer's and Parkinson's disease) and mental disorders (e.g., schizophrenia and substance use disorders). Through international recognition, the DBCBB receives tissue requests from a large number of neuroscientists from Canada and abroad. These continued efforts ensure that the platform will keep fuelling ground-breaking neuroscience research that will have immense potential for impact in the future, including identifying, screening and treatment for brain disorders. Dr. Marie-Christine Guiot, Goodman Cancer Institute and The Neuro (Montreal Neurological Institute-Hospital), McGill University Total grant amount: $570,000.00 The Histology Innovation Platform is a specialized facility that helps scientists study the brain at a cellular level to better understand neurological diseases like Alzheimer's, brain cancer, and epilepsy. Through offering services such as tissue preparation, staining, and advanced imaging, as well as supporting research using technologies that map gene and protein activity within intact tissues, the platform acts as a key resource for projects that aim to find new treatments, diagnostic tools, and ways to improve patient outcomes by exploring how different brain cells interact and change in disease. By supporting this platform, Brain Canada is helping to advance research that could lead to better treatments for neurological diseases, ultimately improving the health and well-being of Canadians. Dr. Nadia Gosselin, CIUSSS du Nord de l'Île-de-Montréal and Université de Montréal Total grant amount: $2,137,500.00 The SLEEP HUB is an innovative platform aimed at advancing sleep research and fostering collaborations at the local, national, and international level. Integrating three key resources, the Nights Bank, the Canadian Sleep Research Biobank, and the Snooz Toolbox, SLEEP HUB provides a vast collection of samples and data, including over 50,000 biological samples and sleep recordings from 15,000 participants. With the aim of developing a more integrated platform that will facilitate access to biological samples, sleep recordings and sleep analysis tools, SLEEP HUB will facilitate analyses on large samples and rare sleep disorders by providing researchers with access to polysomnographic recordings and biological samples. This robust platform infrastructure will transform our understanding and treatment of sleep disorders, which will benefit cognitive, physical and mental health. Dr. Paul Cisek, Centre for Biomedical Innovation, Université de Montréal Total grant amount: $855,000.00 Technological advances such as wireless recording and AI-based automated quantification of behavior allow neuroscience to address the complexity of real behavior under naturalistic conditions. This allows scientists to better understand how different systems (e.g., perceptual, motor, cognitive, emotional, etc.) are seamlessly integrated during real-time interactions with the environment. The EthoLab will make use of these advances to establish a cutting-edge, shared experimental platform that will enable a wide range of neurophysiological experiments with freely moving animals. This platform will make it possible to study situations that capture the complexity of natural behavior and yield insights into the human brain that will translate to clinical applications with impacts in the real-world. Dr. Pia Wintermark, The Montreal Children's Hospital and The Research Institute of the McGill University Health Centre (Child Health and Human Development Program) Total grant amount: $1,710,000.00 Hypoxic-ischemic encephalopathy (HIE) can be caused at birth when babies do not receive enough oxygen to their brain and organs. While this life-threatening condition is responsible for 23% of babies' deaths worldwide and often results in difficulties with learning and everyday functioning, there is currently no treatment to repair brain damage caused by HIE. The NECTAr platform will address this gap by creating a national, collaborative, and multidisciplinary platform focused on improving the care and long-term outcomes of babies with HIE. More specifically, the platform's priorities include improving early treatments by collecting extensive data and comparing practices across hospitals, developing and testing new therapies to repair brain damage, empowering parents through their journey, and training the next generation of doctors and scientists to care for these vulnerable babies.
Globe and Mail
13-05-2025
- Globe and Mail
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ('HCWB' or the 'Company') (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor - T cells (CAR-Ts) for immunotherapy with increased function. HCW9206 is a novel class of immunotherapeutic that enables a single molecule to deliver synergistic signals from three different immune-stimulatory cytokines. The activity of HCW9206 was significantly superior compared to standard methods employing anti-CD3/anti-CD28 and IL-2 reagents for CAR lentiviral transduction and subsequent expansion and persistence of human CAR-Ts. CAR-Ts represent a revolutionary technology with several CD19-specific CAR-T therapies approved by the FDA for the treatment of B-cell malignancies, and CAR-Ts continue to play an increasingly pivotal and expanding role in the treatment of cancer and has significant potential to treat autoimmune diseases and age-related diseases. The Company's research collaborator Dr. Harris Goldstein's laboratory at the Albert Einstein College of Medicine, Bronx, New York, recently presented findings of these studies at the 2025 Annual Meeting of American Association of Immunologists (AAI 2025), Honolulu, HI. The poster presentation reported that HCW9206 is not only a better reagent than the current anti-CD3/anti-CD28/IL-2 method for CAR-T viral transduction, it also effectively expanded stem cell-like memory T cells (T scm) carrying the CAR constructs. It is well established that the T scm subset of T cells exhibits more in vivo persistence and targeted cell killing than other subsets of T cells, including memory T cells, following adoptive transfer into patients. In experimental humanized models in mice, adoptively transferred HCW9206-generated HIV- and CD19-specific CAR-Ts displayed more potency in suppressing HIV-1 and leukemic cells with enhanced persistence, respectively, when compared with the same CD-19-specific CAR-Ts generated with standard methods. The results of these studies represent an alternative novel strategy for CAR-T cell production with the advantage of generating a large population of CAR-Ts with a T scm cell phenotype, which should enhance the persistence of CAR-Ts in patients. This strategy will likely improve long-term survival of disease-specific CAR-Ts following adoptive transfer and enable sustained suppression of malignancies, chronic infections and autoimmune diseases. Dr. Hing C. Wong, the Founder and CEO of the Company, commented, 'HCW9206 is a promising revolutionary reagent to replace anti-CD3/anti-CD28/IL-2-based approaches to streamline and lower the costs of CAR-T manufacturing. Equally important, HCW9206 can improve the functional activities and persistence of CAR-Ts following adoptive transfer, a goal that has not been achieved for the last decade. Also, it provides us with an in-road opportunity to participate in the development of the highly promising, emergent 'in-vivo CAR-T manufacturing technology'. The GMP master cell bank of HCW9206 and its manufacturing process has been established, and its drug master file as an ex vivo reagent has also been filed with the US Food and Drug Administration. The Company is now seeking commercial partnerships for HCW9206 reagent sale and/or integration into CAR-T based manufacturing processes. You could find more about the presentation on HCW9206 at AAI 2025, entitled, 'Generation of HIV- and CD19-Specific TSCM CAR-T Cells by a Novel Cytokine-Based Scaffold,' using the link below: AAI2025 About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and possibly extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is such a versatile scaffold that it enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at Forward Looking Statements: Statements in this press release contain 'forward-looking statements' that are subject to substantial risks and uncertainties. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'expect,' 'believe,' 'will,' 'may,' 'should,' 'estimate,' 'project,' 'outlook,' 'forecast' or other similar words and include, the efficacy of HCW9206 for generating CAR-T's for immune cell therapy; and the ability of HCW9206 preclinical studies to translate into human trials to activate T scm cells in patients; the ability of HCW9206 to improve long-term survival of disease-specific CAR-Ts following adoptive transfer and enable sustained suppression of malignancies, chronic infections and autoimmune diseases. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled 'Risk Factors' in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the 'SEC') on March 28, 2025 and in other filings filed from time to time with the SEC. Company Contact:
Globe and Mail
11-04-2025
- Globe and Mail
Recipient of the Dr. Sudipta Mohanty Scholarship for Healthcare Equity Announced
Boston, MA - The Dr. Sudipta Mohanty Scholarship for Healthcare Equity is thrilled to unveil its very first awardee. This unique $1,000 scholarship, initiated by Dr. Sudipta Mohanty, aims to uplift undergraduate students and aspiring physicians who are driven to enhance healthcare availability for underserved populations. Dr. Sudipta Mohanty, a devoted physician and champion of fair healthcare, launched this program to nurture the ambitions of students eager to tackle disparities in medical access. The impressive volume of applications received from across the country underscores the rising dedication among young healthcare enthusiasts to transform primary care and uplift community wellness. Supporting Tomorrow's Healthcare Pioneers The Dr. Sudipta Mohanty Scholarship for Healthcare Equity is designed to bolster students who are passionate about primary care and serving overlooked communities. Candidates were tasked with submitting an essay exploring medicine's role in underserved regions and offering creative ideas to boost healthcare reach. On March 15, 2025, one exceptional student was named the scholarship's inaugural recipient. This individual's essay will be showcased, celebrating their commitment to healthcare justice and their promise as a future leader in the field. Dr. Sudipta Mohanty shared his excitement about the scholarship's mission: 'As a physician, I've witnessed the struggles underserved groups face in securing proper medical care. This scholarship is my effort to inspire and equip the next wave of healthcare providers to close these divides. The future of medicine hinges on compassionate, equity-focused individuals.' Dr. Sudipta Mohanty's Legacy of Care Dr. Sudipta Mohanty has built a career rooted in primary care, health advocacy, and teaching. His remarkable journey saw him begin college at age 15, later earning a medical degree from the University of Pittsburgh and completing residency training at the University of California Riverside. This path sharpened his focus on patient-first care and health system improvements. A tireless proponent of expanding healthcare access, Dr. Mohanty's scholarship embodies his lifelong mission by aiding students who share his vision for change in underserved regions. Countdown to March 15, 2025 The review process for the Dr. Sudipta Mohanty Scholarship for Healthcare Equity completed with a panel carefully evaluating submissions to select a winner who reflects the initiative's core values. The chosen student was announced on March 15, 2025, with their inspiring story spotlighted to motivate others in the medical community. This scholarship not only provides financial aid but also fosters dialogue about making healthcare more inclusive. Dr. Sudipta Mohanty is eager to sustain this effort, championing the development of future healthcare trailblazers. For additional details about the Dr. Sudipta Mohanty Scholarship for Healthcare Equity and upcoming opportunities, visit Media Contact Company Name: Dr. Sudipta Mohanty Scholarship Contact Person: Dr. Sudipta Mohanty Email: Send Email City: Boston State: Massachusetts Country: United States Website:
